**Psilocybin Advisory Board Research Subcommittee meeting**

April 14, 2021

Subcommittee Members in Attendance:

1) Todd Korthuis

2) Atheir Abbas

3) Tom Jeanne

4) Ali Hamada

5) Jessie Uehling

6) Tom Jeanne

7) Christopher Stauffer

8) Angela Carter

1. Introductions

-Dr. Chris Stauffer introduced as new Research Subcommittee member

2. Review of Measure 109, section 11

-June 30, 2021 deadline

3. Consensus achieved around review process:

* Goal for June 30 is list of existing publications from peer reviewed sites with brief summary of domains; not meant to be exhaustive systemic review for publication; results will be posted publically by OHA
* Focus on review of systematic reviews
* Exclusive focus on psilocybin (rather than literature on LSD, MDMA, etc.)
* Members will forward list of potential publications to Nic Riley, for now.

4. Consensus around domains for June 30 review:

a) Safety – Atheir Abbas to lead summary; Ali Hamada agreed to help; consider the following domains:

-Interpersonal risks

-Medical risks

-Psychological risks

-Vulnerable populations (potentially overlapping with above?)

-Healthcare utilization (e.g. ED visits –potential overlap with above?)

-Consider role of psilocybin dose and species in terms of safety

b) Efficacy –Todd Korthuis to lead summary; hoping others will join; Domains may include treatment for:

- Depression

- Anxiety/PTSD

- Alcohol use disorder

- Tobacco use disorder

- Other drug use disorder

-End of life/palliative care

-Wellness/Health promotion/spiritual growth

c) Production/mycology – Jessie Uehling to lead summary

- Psilocybin mushroom species available in Oregon

- Best practice for mushroom growth/handling

- Manufacturing sources?

5. Need to incorporate traditional cultures/oral narratives into summary of knowledge

- Angela Carter and others to forward published literature to Nic Riley

- Consensus that this information may be more difficult to find and may need to be incorporated over time, beyond June 30th.

6. Consensus on need for methodologic expertise in systematic reviews; OK to make informal contacts with Oregon experts who might be willing to volunteer their time to assist with June 30 product; acknowledgement that this may lead to a more rigorous systematic review following June 30th.

7. Consensus to try to meet every 2 weeks through June 30th.